Pharmacokinetics of ribavirin in combined interferon-alpha 2b and ribavirin therapy for chronic hepatitis C virus infection
about
A pharmacological profile of ribavirin and monitoring of its plasma concentration in chronic hepatitis C infectionRole of erythrocytes as a reservoir for ribavirin and relationship with adverse reactions in the early phase of interferon combination therapy for chronic hepatitis C virus infections.Telaprevir and ribavirin interaction: higher ribavirin levels are not only due to renal dysfunction during triple therapy.Several factors including ITPA polymorphism influence ribavirin-induced anemia in chronic hepatitis C.Multiplex liquid chromatography-tandem mass spectrometry assay for simultaneous therapeutic drug monitoring of ribavirin, boceprevir, and telaprevir.Ribavirin in the treatment of chronic hepatitis C.The utility of therapeutic drug monitoring for ribavirin in patients with chronic hepatitis C--a critical review.ENT1, a ribavirin transporter, plays a pivotal role in antiviral efficacy of ribavirin in a hepatitis C virus replication cell system.Ribavirin steady-state plasma level is a predictor of sustained virological response in hepatitis C-infected patients treated with direct-acting antivirals.Variant Inosine Triphosphatase Phenotypes Are Associated With Increased Ribavirin Triphosphate Levels.Pharmacogenetics of ribavirin-induced anemia in HCV patients.Relationship between inosine triphosphate genotype and outcome of extended therapy in hepatitis C virus patients with a late viral response to pegylated-interferon and ribavirin.Treatment effects and predictors of a 24-week course of interferon alpha-2b plus ribavirin combination therapy for patients with chronic hepatitis C.Influence of HCV genotype 1 subtypes on the virus response to PEG interferon alpha-2a plus ribavirin therapy.Response to peginterferon-alfa 2b and ribavirin in Japanese patients with chronic hepatitis C genotype 2.Pharmacokinetics and enhanced PKR response in patients with chronic hepatitis C treated with pegylated interferon alpha-2b and ribavirin.Contribution of ribavirin transporter gene polymorphism to treatment response in peginterferon plus ribavirin therapy for HCV genotype 1b patients.Neuroprotective Drug for Nerve Trauma Revealed Using Artificial Intelligence.Ribavirin rather than PEG-interferon pharmacodynamics predict nonresponse to antiviral therapy in naive chronic hepatitis C patients.Monographs on drugs which are frequently analyzed in therapeutic drug monitoring/Arzneimittel-Monographien für Medikamente, die regelmäßig im Rahmen des Therapeutic Drug Monitorings analysiert werdenAssessment of hepatitis C virus-RNA clearance under combination therapy for hepatitis C virus genotype 1: performance of the transcription-mediated amplification assayRibavirin at the Era of Novel Direct Antiviral Agents for the Treatment of Hepatitis C Virus Infection: Relevance of Pharmacological Monitoring
P2860
Q27023355-5A574025-B76A-417B-A5CB-F1C1A2ADDE32Q35073553-1DB5818D-DBBA-4048-9124-9382FD57EE52Q35607785-F853596C-2754-4999-9B49-757D56ADBB02Q36378784-8A33D9D5-A0D4-40DD-B853-E938F918DDCBQ36969893-882BEE31-5BF8-47F4-B805-1577A93DF745Q37195248-DADA35C9-98EF-4D9E-AC54-C9F3AEC45BBDQ37634196-F271B556-1407-4204-9530-501ACD439714Q39414574-A4C6A192-4D55-4848-B0D3-1021DF8040C6Q40053677-E3E64676-D70E-4BAD-8BEC-CF01FD5287DEQ40385212-4BF9BB83-F935-4C80-92E2-19ECF628DAE7Q40650428-3F9F43F9-26D3-4DBF-A05D-405A3EFACC26Q42274008-3EC10795-D39F-44EC-81BD-9032BDD42D16Q43001086-85BEA538-6C88-4360-913A-D34B649FFE38Q43033729-7FA49AF9-0E45-4F58-B47A-9A2586E4F213Q43037030-F28524E3-152E-4467-A7FB-2A7EF2D07782Q43037733-4AD71CBC-3827-499A-B179-D3FDCFDF9BE2Q43047106-1B928C22-2648-48C2-B132-16BDC4F31404Q47554585-5E964E77-65B8-4380-840F-D499F393D94BQ50558050-716BFC2D-8D76-4D52-ABB1-FE4B718BAEF4Q57550192-BAD396AA-0207-4E3A-9679-DBF5F26E2D8CQ58803325-706FC840-39E0-4E25-A747-1C8250B517D1Q59049605-F45B7484-4EED-4AB0-8810-91825AE1C717
P2860
Pharmacokinetics of ribavirin in combined interferon-alpha 2b and ribavirin therapy for chronic hepatitis C virus infection
description
2003 nî lūn-bûn
@nan
2003年の論文
@ja
2003年論文
@yue
2003年論文
@zh-hant
2003年論文
@zh-hk
2003年論文
@zh-mo
2003年論文
@zh-tw
2003年论文
@wuu
2003年论文
@zh
2003年论文
@zh-cn
name
Pharmacokinetics of ribavirin ...... ic hepatitis C virus infection
@ast
Pharmacokinetics of ribavirin ...... ic hepatitis C virus infection
@en
type
label
Pharmacokinetics of ribavirin ...... ic hepatitis C virus infection
@ast
Pharmacokinetics of ribavirin ...... ic hepatitis C virus infection
@en
prefLabel
Pharmacokinetics of ribavirin ...... ic hepatitis C virus infection
@ast
Pharmacokinetics of ribavirin ...... ic hepatitis C virus infection
@en
P2093
P2860
P1476
Pharmacokinetics of ribavirin ...... ic hepatitis C virus infection
@en
P2093
Akihito Tsubota
Hiromitsu Kumada
Namiki Izumi
Yuichi Hirose
P2860
P304
P356
10.1046/J.1365-2125.2003.01780.X
P407
P577
2003-04-01T00:00:00Z